The researcher, who was awarded a Young Talent Grant by the DiabetesCERO Foundation, is conducting research linked to INiBICA’s CO17 group that focuses on the anti-inflammatory potential of marine-derived compounds

 

The recent interview with Dr. Almudena Lara published by the DiabetesCERO Foundation highlights a line of research closely linked to the work of the group “ CO17: , Diabetes Mellitus – Autoimmunity and Chronic Complications: Pathological, Clinical, and Therapeutic Implications” at the Institute for Biomedical Research and Innovation (INiBICA) at Cádiz.

Dr. Lara has been awarded a Young Talent Grant from the DiabetesCERO Foundation for a project focused on the study of marine molecules with anti-inflammatory potential—an innovative approach that opens up new perspectives in addressing diabetes-related processes and their immunological mechanisms.

The CO17 group conducts basic, translational, and applied research on diabetes mellitus, its chronic complications, and new therapeutic approaches. Its work focuses on the study of diabetes, autoimmunity, and the complications associated with this disease, with the goal of advancing our understanding of its pathological, clinical, and therapeutic implications.

Investigación conectada con el entorno marino de Cádiz

 

In this context, Dr. Lara’s work with marine-derived molecules reinforces INiBICA’s commitment to innovative, translational research linked to the unique environment of the province of Cádiz. This line of research also aligns with the institute’s interest in fostering collaborations related to marine resources applied to health.

Reconocimiento al talento investigador joven/b>

 

The DiabetesCERO Foundation’s recognition helps raise the profile of young research talent and highlights the importance of supporting Projects , which explores new strategies to advance our understanding of diabetes and the development of future therapeutic alternatives.

🔗 More information: DiabetesCERO